Skip to main content

Nanogen Appoints Gerald Wills as CFO

NEW YORK, April 30 - Nanogen has appointed Gerald Wills, formerly the chief
financial officer of Trega Biosciences, as its vice president and chief financial officer, the San Diego-based company said Monday.

Wills, 48, will replace the current CFO Kieran Gallahue, who will now work solely as president of Nanogen.

Wills served in his position at Trega from 1999 until it was acquired by Lion Biosciences in March. Previously, Wills was chief financial officer of cardiac testing biotech company Molecular Biosystems.

Additionally, Nanogen reported that Randy White, the executive vice president of technical operations and R&D at American Medical Laboratories, has joined the company's board of directors.

Recently, White facilitated a collaboration between Nanogen and AML. Nanogen hopes the deal will lead to the development of molecular diagnostic assays for its NanoChip molecular biology workstation.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.